Gliclazide is an oral sulfonylurea hypoglycemic agent which stimulates insulin secretion which stimulates beta cells of the islet of Langerhans in the pancreas to release insulin.
Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type.
The company intends to launch the product in July 2011.
It has been marketed as Glyloc and Reclide in India and Diamicron in Canada.